Description: Mydecine Innovations Group Inc. operates as a biopharma and life sciences company which focuses on research, development, acceptance, and commercialization of alternative nature-sourced medicine for treating mental health problems. Its mental health solutions focuses on clinical trials focusing on veterans; emergency medical services (EMS); first responders with a PTSD indication; and drug discovery and delivery mechanisms. The company develops digital health solutions, such as digital therapeutics and quantified mental health solutions. Additionally, it engages in the operation of real estate and farm properties in North America. The company was formerly known as NewLeaf Brands Inc. and changed its name to Mydecine Innovations Group Inc. in June 2020. Mydecine Innovations Group Inc. is headquartered in Vancouver, Canada.
Home Page: www.mydecine.com
789 West Pender Street
Vancouver,
BC
V6C 1H2
Canada
Phone:
720 277 9879
Officers
| Name | Title |
|---|---|
| Mr. David Joshua Bartch | Co-Founder, CEO, Pres & Chairman |
| Mr. Robert Roscow M.A. | Co-Founder, Chief Scientific Officer & Director |
| Mr. Damon Michaels | Co-Founder & COO |
| Mr. Sanford M. Stein | Chief Compliance Officer, Gen. Counsel & Corp. Sec. |
| Dr. Rakesh Jetly FRCPC, M.D. | Chief Medical Officer |
| Mr. John Charles Ross CA, CPA, M.B.A. | Chief Financial Officer |
| Morgan Kervitsky | Director of Marketing |
| Mr. Michel Rudolphie | Pres of the European Operations |
| Mr. William Cook | Interim CEO & Technical Director of Mindleap Health Inc. |
Exchange: OTCMKTS
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 23.4066 |
| Price-to-Sales TTM: | 677.586 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 11 |